UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Inhibiting Adipose Tissue Lipogenesis Reprograms Thermogenesis and PPARγ Activation to Decrease Diet-Induced Obesity

Cell metabolism, 2012-08, Vol.16 (2), p.189-201

2012

Volltextzugriff (PDF)

Simultaneous targeting of B-cell malignancies and human immunodeficiency virus with bispecific chimeric antigen receptor T cells

Haematologica (Roma), 2024-09, Vol.109 (9), p.3053

2024

Volltextzugriff (PDF)

Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma

Blood advances, 2021-01, Vol.5 (1), p.143-155

2021

Volltextzugriff (PDF)

Clinical Validation of KIT Inhibition in Advanced Systemic Mastocytosis

Current hematologic malignancy reports, 2018-10, Vol.13 (5), p.407-416

2018

Volltextzugriff (PDF)

A Primer on Chimeric Antigen Receptor T-cell Therapy-related Toxicities for the Intensivist

Journal of Intensive Care Medicine, 2024-10, Vol.39 (10), p.929-938

2024

Volltextzugriff (PDF)

CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial

Nature medicine, 2021-08, Vol.27 (8), p.1419-1431

2021

Volltextzugriff (PDF)

A phase 2 study of brentuximab vedotin in patients with CD30-positive advanced systemic mastocytosis

Blood advances, 2019-08, Vol.3 (15), p.2264-2271

2019

Volltextzugriff (PDF)

An Unusual Cause of Epistaxis: Paranasal Sinus Myeloid Sarcoma

Case reports in hematology, 2019-01, Vol.2019 (2019), p.1-5

2019

Volltextzugriff (PDF)

Glofitamab stimulates immune cell infiltration of CNS tumors and induces clinical responses in secondary CNS lymphoma

Blood, 2024-07, Vol.144 (4), p.457-461

2024

Volltextzugriff (PDF)

Real‐world experience of axicabtagene ciloleucel, a CD19‐directed CAR T‐cell therapy, in the second‐line treatment of early relapsed or primary refractory large B‐cell lymphoma

British journal of haematology, 2024-07, Vol.205 (1), p.368-372

2024

Volltextzugriff (PDF)

Bendamustine lymphodepletion is a well‐tolerated alternative to fludarabine and cyclophosphamide lymphodepletion for axicabtagene ciloleucel therapy for aggressive B‐cell lymphoma

American journal of hematology, 2023-11, Vol.98 (11), p.1751-1761

2023

Volltextzugriff (PDF)

Interferon-γ blockade in CAR T-cell therapy–associated macrophage activation syndrome/hemophagocytic lymphohistiocytosis

Blood advances, 2023-02, Vol.7 (4), p.533-536

2023

Volltextzugriff (PDF)

Long-Term Follow-Up of Bridging Therapies Prior to CAR T-Cell Therapy for Relapsed/Refractory Large B Cell Lymphoma

Cancers, 2023-03, Vol.15 (6), p.1747

2023

Volltextzugriff (PDF)

Lactate dehydrogenase to carboxyhemoglobin ratio as a biomarker of heme release to heme processing is associated with higher tricuspid regurgitant jet velocity and early death in sickle cell disease

American journal of hematology, 2021-09, Vol.96 (9), p.E315-E318

2021

Volltextzugriff (PDF)

COVID-19 and Other Viral Infections in Patients With Hematologic Malignancies

American Society of Clinical Oncology educational book, 2023-05, Vol.43 (43), p.e390778-e390778

2023

Volltextzugriff (PDF)

Clinical features of neurotoxicity after CD19 CAR T-cell therapy in mantle cell lymphoma

Blood advances, 2024-03, Vol.8 (6), p.1474-1486

2024

Volltextzugriff (PDF)

Voriconazole‐induced periostitis after allogeneic stem cell transplantation

American journal of hematology, 2015-06, Vol.90 (6), p.574-575

2015

Volltextzugriff (PDF)

PB2346: ZUMA‐24: A PHASE 2, OPEN‐LABEL, MULTICENTER STUDY OF AXICABTAGENE CILOLEUCEL IN PATIENTS WITH RELAPSED/REFRACTORY LARGE B‐CELL LYMPHOMA GIVEN WITH CORTICOSTEROIDS IN THE OUTPATIENT SETTING

HemaSphere, 2023-08, Vol.7 (S3), p.e50042ff-n/a

2023

Volltextzugriff (PDF)

Oscillatory haematopoiesis in adults with sickle cell disease treated with hydroxycarbamide

British journal of haematology, 2015-03, Vol.168 (5), p.737-746

2015

Volltextzugriff (PDF)

Generation of Bi-Specific Chimeric Antigen Receptor (CAR) T Cell Therapy for the Treatment of AIDS-Related B Cell Malignancies from Healthy Donors and HIV Patients

Blood, 2023-11, Vol.142 (Supplement 1), p.6822-6822

2023

Volltextzugriff (PDF)

Promising Safety and Anti-Lymphoma Efficacy of Autologous Pmb-CT01 (BAFFRCAR T Cell) Therapy in a First-in-Human Phase 1 Study

Blood, 2023-11, Vol.142 (Supplement 1), p.221-221

2023

Volltextzugriff (PDF)

CD19-Directed CAR T-Cells (CD19-CAR) Combined with Acalabrutinib Achieves Durable Remissions in Patients with Relapsed or Refractory (r/r) Mantle Cell Lymphoma (MCL)

Blood, 2023-11, Vol.142 (Supplement 1), p.4840-4840

2023

Volltextzugriff (PDF)

1 – 25 von 403

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(346)
Mit Volltextzugriff
(306)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

Englisch
(401)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(239)
Life Sciences & Biomedicine
(194)
Humans
(142)
Male
(68)
Female
(67)
Biological And Medical Sciences
(61)
Animals
(59)
Medical Sciences
(48)
Middle Aged
(41)
Adult
(38)
Aged
(35)
Multidisciplinary Sciences
(24)
Science & Technology - Other Topics
(23)
Genetics & Heredity
(20)
Biochemistry & Molecular Biology
(19)
Fundamental And Applied Biological Sciences. Psychology
(19)
Genome-Wide Association Study
(19)
Physical Sciences
(19)
Child
(17)
Neurosciences & Neurology
(17)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Post-infusion CAR TReg cells identify patients resistant to CD19-CAR therapy

Inhibiting Adipose Tissue Lipogenesis Reprograms Thermogenesis and PPARγ Activation to Decrease Diet-Induced Obesity

Simultaneous targeting of B-cell malignancies and human immunodeficiency virus with bispecific chimeric antigen receptor T cells

Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma

Clinical Validation of KIT Inhibition in Advanced Systemic Mastocytosis

A Primer on Chimeric Antigen Receptor T-cell Therapy-related Toxicities for the Intensivist

CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial

A phase 2 study of brentuximab vedotin in patients with CD30-positive advanced systemic mastocytosis

An Unusual Cause of Epistaxis: Paranasal Sinus Myeloid Sarcoma

Determinants of resistance to engineered T cell therapies targeting CD19 in large B cell lymphomas

CD22-directed CAR T-cell therapy induces complete remissions in CD19-directed CAR–refractory large B-cell lymphoma

Glofitamab stimulates immune cell infiltration of CNS tumors and induces clinical responses in secondary CNS lymphoma

Real‐world experience of axicabtagene ciloleucel, a CD19‐directed CAR T‐cell therapy, in the second‐line treatment of early relapsed or primary refractory large B‐cell lymphoma

Bendamustine lymphodepletion is a well‐tolerated alternative to fludarabine and cyclophosphamide lymphodepletion for axicabtagene ciloleucel therapy for aggressive B‐cell lymphoma

Interferon-γ blockade in CAR T-cell therapy–associated macrophage activation syndrome/hemophagocytic lymphohistiocytosis

Long-Term Follow-Up of Bridging Therapies Prior to CAR T-Cell Therapy for Relapsed/Refractory Large B Cell Lymphoma

Lactate dehydrogenase to carboxyhemoglobin ratio as a biomarker of heme release to heme processing is associated with higher tricuspid regurgitant jet velocity and early death in sickle cell disease

COVID-19 and Other Viral Infections in Patients With Hematologic Malignancies

Clinical features of neurotoxicity after CD19 CAR T-cell therapy in mantle cell lymphoma

Voriconazole‐induced periostitis after allogeneic stem cell transplantation

PB2346: ZUMA‐24: A PHASE 2, OPEN‐LABEL, MULTICENTER STUDY OF AXICABTAGENE CILOLEUCEL IN PATIENTS WITH RELAPSED/REFRACTORY LARGE B‐CELL LYMPHOMA GIVEN WITH CORTICOSTEROIDS IN THE OUTPATIENT SETTING

Oscillatory haematopoiesis in adults with sickle cell disease treated with hydroxycarbamide

Generation of Bi-Specific Chimeric Antigen Receptor (CAR) T Cell Therapy for the Treatment of AIDS-Related B Cell Malignancies from Healthy Donors and HIV Patients

Promising Safety and Anti-Lymphoma Efficacy of Autologous Pmb-CT01 (BAFFRCAR T Cell) Therapy in a First-in-Human Phase 1 Study

CD19-Directed CAR T-Cells (CD19-CAR) Combined with Acalabrutinib Achieves Durable Remissions in Patients with Relapsed or Refractory (r/r) Mantle Cell Lymphoma (MCL)

Suchergebnisse filtern